Clinical trial NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis
Official title: A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Primary Biliary Cholangitis
Lead sponsor: COUR Pharmaceutical Development Company, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-03
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

Detailed description: Subjects ages 18-75 with primary biliary cholangitis will be screened up to 14 days prior to enrollment into the study. Screening will be completed to assess eligibility, obtain vital signs, collect laboratory samples and PD measurements, and to receive a FibroScan for liver fibrosis. Subjects will additionally complete an initial PBC-40 assessment and begin an Itch Diary, a questionnaire and scoring system to be completed by the patient every morning and evening through Day 120 and then monthly through end of study.

Subjects who meet all inclusion and no exclusion criteria after completing the screening visit will be enrolled in the study. Subjects will be randomized on Day 1 in a 1:1 ratio to receive either CNP-104 or Placebo (0.9% Sodium Chloride USP) by intravenous (IV) infusion. Subjects will be administered CNP-104 or Placebo on Day 1 and on Day 8. This study was originally designed with 2 cohorts, Cohort 1 comprised of 6 subjects randomized 1:1 to placebo or 4 mg/kg, and Cohort 2 comprised of up to 34 subjects randomized 1:1 to placebo or 8 mg/kg. Under Protocol Amendment 6 (v7.0), the remaining subjects for Cohort 2 (approximately 16) will be randomized 1:3:1 to placebo, 4 mg/kg, and 8 mg/kg respectively.

Subjects will remain in the clinic on Day 1 and Day 8 from the time of admission (prior to administration of CNP-104 or Placebo) through the final procedure conducted 4 hours post-dose that same day unless an infusion reaction, or other adverse event, requires an extended duration of monitoring. Subjects will be discharged if safety parameters are acceptable to the investigator.

Seven days after the second administration of CNP-104 or Placebo, subjects must return to the clinic for collection of safety labs, PD measurements, and assessment of AEs and medication changes.

Subjects will continue to be followed for 2 years to assess safety, pharmacodynamics, and immunogenicity during the Post-Dosing period.

Eligibility criteria: Inclusion Criteria:

1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant women, ages 18-75 years inclusive.
3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:

   1. Alkaline phosphatase \> 1.5× ULN for at least 6 months
   2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\])
   3. Liver biopsy findings consistent with PBC
4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN.
5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
6. Subjects with ALP \> 1.5× ULN.
7. Subjects with AST and ALT \< 5× ULN.
8. Subjects with hemoglobin ≥ 10 g/dL.
9. Subjects with total bilirubin \< 2× ULN.
10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
12. Male subjects who agree to not donate sperm starting at screening and through Day 90.

Exclusion Criteria:

1. Subjects with a Class B or Class C Child-Pugh score.
2. Subjects with concomitant liver diseases including chronic viral hepatitis B or C, autoimmune hepatitis, PSC, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's syndrome.
3. Subjects who have previously undergone liver transplantation.
4. Subjects with decompensated liver disease as defined by the presence or history of any of the following:

   * MELD score \> 15
   * Hepatic encephalopathy
   * Ascites
   * Hepatorenal syndrome or serum creatinine \> 2 mg/dL
   * Total Bilirubin \> 3.0 mg/dL
   * INR \>1.8 unless on anticoagulation such as Coumadin
   * History of variceal hemorrhage
5. Subjects with a history of cerebrovascular accident in the past 12 months.
6. Subjects with history of myocardial infarction, as defined by any of the following criteria:

   * Development of pathological Q waves with or without symptoms
   * Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause
   * Pathological findings of a healed or healing myocardial
7. Subjects with chronic kidney disease, as defined by estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 for at least 3 months (per CKD EPI Equation - 2021).
8. Subjects with uncontrolled diabetes, as defined by HbA1c \> 7%.
9. Subjects who have used the following medications:

   * Methotrexate within 90 days of screening.
   * Immunotherapy drugs unless approved by the medical monitor.
10. Subjects with a history of tuberculosis or positive PPD skin test.
11. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to screening or are planning to receive any vaccination before Day 90.
12. Subjects who have used systemic steroids within 3 months prior to screening.
13. Subjects with laboratory test results at screening or prior to study dosing that are outside the normal limits and considered by the Investigator to be clinically significant.

    Note: This criterion does not apply to liver function tests. Additionally, clinically significant laboratory test results at screening that are related to the condition (PBC) are acceptable as long as all inclusion and no other exclusion criteria are met.
14. Subjects with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at screening.
15. Subjects with a history of or currently active immune disorders other that PBC (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
16. Subjects with a history of or current active diseases requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
17. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.
18. Subjects with a complication or medical history of malignancy within past 5 years which, in the Investigator's opinion, makes the subject unsuitable for study participation.
19. Subjects who, in the Investigator's opinion, will be unable to adhere to study procedures.
20. Subjects who have received an investigational therapy other than CNP-104 within 28 days or 5 half-lives, whichever is longer, prior to screening.
21. Subjects with any condition which, in the Investigator's opinion, makes the subject unsuitable for study participation.
22. Known sensitivity to any components of CNP-104.

Primary outcomes:
measure: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: through Study Completion, an average of 720 Days
measure: Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis).
timeFrame: through Study Completion, an average of 720 Days
measure: Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ)
timeFrame: through CNP-Dosing Period, an average of 15 Days
Secondary outcomes:
measure: To assess the change from baseline in Serum Alkaline Phosphatase (ALP) levels, for safety only
timeFrame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
measure: To assess the change from baseline in AMA
timeFrame: through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days
measure: To assess the change from baseline in liver fibrosis by FibroScan
timeFrame: through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days
measure: To assess the change from baseline in modified PBC-40 score
timeFrame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
measure: To assess the change from baseline in Weekly Mean Itch Score
timeFrame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 D
measure: To assess the change from baseline in liver enzymes (Albumin, Bilirubin (total and direct), ALT, AST, GGT)
timeFrame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
measure: To assess the change in antigen specific CD4+ and CD8+ T cells
timeFrame: through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
Other outcomes:
Locations:
city: Coronado
country: United States
facility: Southern California Research Center
state: California
city: Lancaster
country: United States
facility: OM Research
state: California
city: Sacramento
country: United States
facility: University of California Davis Health
state: California
city: Colorado Springs
country: United States
facility: Peak Gastroenterology Associates
state: Colorado
city: New Haven
country: United States
facility: Yale School of Medicine
state: Connecticut
city: Gainesville
country: United States
facility: University of Florida - Hepatology Research
state: Florida
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
city: Lakewood Ranch
country: United States
facility: Florida Research Institute
state: Florida
city: Naples
country: United States
facility: GI PROS Research
state: Florida
city: Weston
country: United States
facility: Cleveland Clinic - Florida
state: Florida
city: Atlanta
country: United States
facility: Digestive Healthcare of Georgia
state: Georgia
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Novi
country: United States
facility: Henry Ford Health System
state: Michigan
city: Saint Louis
country: United States
facility: Washington University School of Medicine in St. Louis
state: Missouri
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: San Antonio
country: United States
facility: Texas Liver Institute
state: Texas
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: UC Davis
name: Christopher Bowlus, MD
role: PRINCIPAL_INVESTIGATOR
References: